AU2003248356A1 - Beta3-adrenergic receptor agonists - Google Patents
Beta3-adrenergic receptor agonistsInfo
- Publication number
- AU2003248356A1 AU2003248356A1 AU2003248356A AU2003248356A AU2003248356A1 AU 2003248356 A1 AU2003248356 A1 AU 2003248356A1 AU 2003248356 A AU2003248356 A AU 2003248356A AU 2003248356 A AU2003248356 A AU 2003248356A AU 2003248356 A1 AU2003248356 A1 AU 2003248356A1
- Authority
- AU
- Australia
- Prior art keywords
- beta3
- receptor agonists
- adrenergic receptor
- adrenergic
- agonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000048 adrenergic agonist Substances 0.000 title 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 title 1
- 102000016959 beta-3 Adrenergic Receptors Human genes 0.000 title 1
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36025102P | 2002-02-27 | 2002-02-27 | |
| US60/360,251 | 2002-02-27 | ||
| PCT/IB2003/000590 WO2003072572A1 (en) | 2002-02-27 | 2003-02-17 | Beta3-adrenergic receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2003248356A1 true AU2003248356A1 (en) | 2003-09-09 |
Family
ID=27766207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003248356A Abandoned AU2003248356A1 (en) | 2002-02-27 | 2003-02-17 | Beta3-adrenergic receptor agonists |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1485379A1 (en) |
| JP (1) | JP2005518448A (en) |
| AU (1) | AU2003248356A1 (en) |
| BR (1) | BR0308070A (en) |
| CA (1) | CA2476316A1 (en) |
| DO (1) | DOP2003000587A (en) |
| GT (1) | GT200300043A (en) |
| MX (1) | MXPA04007127A (en) |
| PA (1) | PA8567701A1 (en) |
| PE (1) | PE20030943A1 (en) |
| TW (1) | TW200408637A (en) |
| UY (1) | UY27680A1 (en) |
| WO (1) | WO2003072572A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002085297A2 (en) | 2001-04-24 | 2002-10-31 | East Carolina University | Compositions & formulations with a non-glucocorticoid steroid &/or a ubiquinone & kit for treatment of respiratory & lung disease |
| US7405207B2 (en) | 2002-06-17 | 2008-07-29 | Epigenesis Pharmaceuticals, Inc. | Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof |
| GB0324654D0 (en) * | 2003-10-22 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
| WO2005061433A2 (en) * | 2003-12-23 | 2005-07-07 | Astellas Pharma Inc. | Aminoalcohol derivatives |
| DE102004021779A1 (en) * | 2004-04-30 | 2005-11-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New beta-agonists, process for their preparation and their use as medicines |
| US8685924B2 (en) | 2004-08-25 | 2014-04-01 | Takeda Pharmaceutical Company Limited | Preventives/remedies for stress urinary incontinence and method of screening the same |
| PE20091825A1 (en) | 2008-04-04 | 2009-12-04 | Merck & Co Inc | HYDROXIMETHYL PYRROLIDINES AS AGONISTS OF THE BETA 3 ADRENERGIC RECEPTOR |
| US20150087832A1 (en) | 2011-10-27 | 2015-03-26 | Merck Sharp & Dohme, Corp. | Process for making beta 3 agonists and intermediates |
| ES2584427T3 (en) | 2011-10-27 | 2016-09-27 | Merck Sharp & Dohme Corp. | Process for the preparation of beta 3 agonists and intermediate products |
| DK2968269T3 (en) | 2013-03-15 | 2019-10-07 | Merck Sharp & Dohme | PROCEDURE FOR PREPARING BETA-3 AGONISTS AND INTERMEDIATES |
| CN110869022A (en) | 2017-06-06 | 2020-03-06 | 乌洛万特科学有限公司 | Using Viberon to Treat Overactive Bladder |
| AU2019393372B2 (en) | 2018-12-05 | 2025-08-21 | Sumitomo Pharma Co., Ltd | Vibegron for the treatment of overactive bladder symptoms |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO179246C (en) * | 1991-11-20 | 1996-09-04 | Sankyo Co | Aromatic amino-alcohol derivatives and intermediates for their preparation |
| AU684352B2 (en) * | 1994-04-08 | 1997-12-11 | Sumitomo Chemical Company, Limited | Ether compound, use thereof, and intermediate for producing the compound |
| WO1996035671A1 (en) * | 1995-05-10 | 1996-11-14 | Pfizer Inc. | β-ADRENERGIC AGONISTS |
| GB9812709D0 (en) * | 1998-06-13 | 1998-08-12 | Glaxo Group Ltd | Chemical compounds |
| CZ20031012A3 (en) * | 2000-10-20 | 2004-04-14 | Pfizer Products Inc. | Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
-
2002
- 2002-03-13 DO DO2003000587A patent/DOP2003000587A/en unknown
-
2003
- 2003-02-17 MX MXPA04007127A patent/MXPA04007127A/en unknown
- 2003-02-17 EP EP03742884A patent/EP1485379A1/en not_active Withdrawn
- 2003-02-17 WO PCT/IB2003/000590 patent/WO2003072572A1/en not_active Ceased
- 2003-02-17 JP JP2003571278A patent/JP2005518448A/en not_active Withdrawn
- 2003-02-17 BR BR0308070-6A patent/BR0308070A/en not_active IP Right Cessation
- 2003-02-17 AU AU2003248356A patent/AU2003248356A1/en not_active Abandoned
- 2003-02-17 CA CA002476316A patent/CA2476316A1/en not_active Abandoned
- 2003-02-24 PE PE2003000180A patent/PE20030943A1/en not_active Application Discontinuation
- 2003-02-25 UY UY27680A patent/UY27680A1/en not_active Application Discontinuation
- 2003-02-26 GT GT200300043A patent/GT200300043A/en unknown
- 2003-02-26 PA PA20038567701A patent/PA8567701A1/en unknown
- 2003-02-26 TW TW092104037A patent/TW200408637A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04007127A (en) | 2005-07-05 |
| CA2476316A1 (en) | 2003-09-04 |
| JP2005518448A (en) | 2005-06-23 |
| DOP2003000587A (en) | 2003-08-30 |
| EP1485379A1 (en) | 2004-12-15 |
| PA8567701A1 (en) | 2003-11-12 |
| WO2003072572A1 (en) | 2003-09-04 |
| BR0308070A (en) | 2004-12-21 |
| TW200408637A (en) | 2004-06-01 |
| GT200300043A (en) | 2003-09-22 |
| UY27680A1 (en) | 2003-10-31 |
| PE20030943A1 (en) | 2003-11-08 |
| WO2003072572A8 (en) | 2004-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003290700A1 (en) | Farnesoid x receptor agonists | |
| AU2003243637A1 (en) | Cannabinoid receptor agonists | |
| AU2003233780A1 (en) | Novel glucagon antagonists/inverse agonists | |
| AU2003236205A1 (en) | Glucagon antagonists/inverse agonists | |
| AU2003224111A1 (en) | Substituted pyrazolo-pyrimidine-4-ones | |
| AU2003231513A1 (en) | Pgd2 receptor antagonist | |
| AU2003241836A1 (en) | Lpa receptor antagonists | |
| AU2003277576A1 (en) | Receptor function controlling agent | |
| IL163928A0 (en) | Pyridinoylpiperidines as 5-htf agonists | |
| WO2003072535A8 (en) | Substituted hydroxyethylamines | |
| AU2003238043A1 (en) | Substituted imidazotriazines | |
| AU2003245984A1 (en) | Hetero-cyclicaly substituted imidazotriazines | |
| AU2003275838A1 (en) | Pyrrolidin-2-on derivatives as ep4 receptor agonists | |
| AU2003303543A1 (en) | Agonist antibody against heteroreceptor | |
| AU2003294900A1 (en) | Substituted 5-aminomethyl-1h-pyrrole-2-carboxamides | |
| AU2003248356A1 (en) | Beta3-adrenergic receptor agonists | |
| AU2003212366A1 (en) | Substituted 4-aminocyclohexanols | |
| AU2003277552A1 (en) | Receptor regulator | |
| AU2003266342A1 (en) | Connecting mechanism | |
| AU2003244313A1 (en) | Androgen receptor agonist | |
| AU2003290284A1 (en) | Deformable-mirror holder | |
| AU2003302405A1 (en) | T-cell receptors | |
| AU2003298683A1 (en) | Cable-testing adapter | |
| AU2003281525A1 (en) | Serotonin receptor | |
| AU2003300867A1 (en) | Uses of the snorf207 receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |